# SO1- Immunization

All countries in the Region providing two- doses of measles-rubella (MR) vaccine through essential immunization programme

Measles Vaccine Coverage: Significant impact of COVID-19 pandemic in 2020

Confirmed measles cases and coverage of MCV1 and MCV2 in SEAR 2000-2021

Legend: India, Indonesia, Myanmar, Thailand, Others, MCV1 coverage, MCV2 coverage

# Rubella Vaccine Coverage in SEAR

Confirmed rubella cases and RCV coverage in SEAR 2005-2021

Impact of COVID-19 pandemic on Measles Rubella Immunization
## (Monthly MRCV-1 coverage 2019, 2020 and 2021 data)

# Supplementary immunization activities conducted to the extent possible

Nearly 39 million children were administered MR vaccine through mass vaccination campaigns in the Region in 2020and early 2021 despite of COVID-19 pandemic

COUNTRY	Type of campaign (M/MR? OB, f/u, c/u, PIRI?)	Original proposed date	Has campaign taken place?	Likely implementation date	Comments
Bangladesh	MR F/U SIA	Mar 2020	Yes	Dec 2020	Completed
Nepal	MR F/U SIA	Mar 2020	YES	June 2020	Completed
India	MR F/U	Q2 2020	No	TBD	
Indonesia	MR F/U Sb Nat	Q4 2020	No	Mar 2022	
Maldives	Selective SIA	Mar 2020	No	Dropped	Cover through RI

Zero-dose and partially vaccinated children significant in 2020 cohort

Country	Under 1 year population	MCV /RCV zero dose children		MCV Partially vaccinated	
		Number	%	Number	%
Bangladesh	3 293 482	98 804	3%	131 739	4%
Bhutan	10 600	742	7%	106	1%
DPR Korea	306 153	3 062	1%	-	0%
India	26 451 880	2 909 707	11%	2 116 150	8%
Indonesia	4 650 109	1 116 026	24%	1 255 529	27%
Maldives	8 853	89	1%	266	3%
Myanmar	927 884	83 510	9%	9 279	1%
Nepal	620 739	80 696	13%	80 696	13%
Sri Lanka	352 554	14 102	4%	-	0%
Thailand	577 133	51 942	9%	-	0%
Timor-Leste	31 905	6 700	21%	319	1%
SEAR	37 231 292	4 365 379	12%	3 594 085	10%

6

Both access and utilization to MCV has significantly reduced in 2020

Data from district or equivalent third admin level from al SEA Region countries

% 3rd admin unit/districts (n=2068)		2019	2020
Access	HIGH (MCV1 ≥95%)	33%	16%
	LOW (MCV1<95%)	67%	84%
Utilization	HIGH (MCV2 dropout <5%)	45%	10%
	LOW (MCV2 dropout ≥5%)	55%	90%

Category -1	Category-2	Categry-3	Categry-4
30%	10%	32%	27%